Silverback Therapeutics (Nasdaq: SBTX) announced its participation in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022. CEO Laura Shawver, Ph.D., will deliver a corporate overview on March 9 at 12:50 p.m. ET. Investors can access the live webcast through Silverback's Investor Relations website, with a replay available for 30 days post-event. The biopharmaceutical company focuses on developing targeted therapeutics for cancer and chronic viral infections using its proprietary ImmunoTAC platform.
Silverback Therapeutics (SBTX), a clinical-stage biopharmaceutical company, announced its participation in the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. CEO Laura Shawver, Ph.D., and President Valerie Odegard, Ph.D., will engage in a fireside chat on February 16 at 1:00 PM ET. The live webcast is accessible on Silverback’s Investor Relations website, with a replay available for 30 days. Silverback focuses on developing targeted immuno-oncology agents through its proprietary ImmunoTAC technology, aimed at treating cancer and chronic viral infections.
Silverback Therapeutics (SBTX), a clinical-stage biopharmaceutical company based in Seattle, has announced its participation in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022. The company focuses on developing tissue-targeted therapeutics for serious diseases utilizing its proprietary ImmunoTAC technology platform. Silverback’s CEO Laura Shawver and President Valerie Odegard will present a corporate overview available on the company's Investor Relations website starting January 10, 2022, at 7:00 AM ET.
Silverback Therapeutics (SBTX) presented a trial-in-progress poster on SBT6050-201 at the SITC 36th Annual Meeting held virtually from November 10-14, 2021. The Phase 1/2 study evaluates SBT6050 in combination with trastuzumab deruxtecan or trastuzumab with tucatinib and capecitabine in patients with HER2-expressing cancers. SBT6050 aims to enhance anti-tumor responses and is currently undergoing evaluation in advanced HER2-expressing tumors. The presentation highlights the potential of SBT6050 to improve therapeutic outcomes in treating these cancers.
Silverback Therapeutics (SBTX) announced preclinical data for SBT8230 at the AASLD 2021 event. SBT8230, designed for chronic hepatitis B virus treatment, features a TLR8 agonist conjugated to ASGR1-specific antibody. Key findings reveal efficient liver delivery and myeloid cell activation only in the liver, leading to reduced HBV surface antigen in AAV-HBV mouse models. Plans for Phase 1-enabling toxicology studies are set for Q1 2022. This progress underscores Silverback's commitment to advancing innovative therapies.
Silverback Therapeutics (NASDAQ: SBTX), a clinical-stage biopharmaceutical company, will participate in the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021. CEO Laura Shawver and President Valerie Odegard will engage in a fireside chat on November 17 at 2:40 PM ET. A live webcast of the event will be accessible on their investor relations website, with a replay available for 30 days. The company focuses on developing tissue-targeted therapeutics for cancer and chronic viral infections using its ImmunoTAC technology platform.
Silverback Therapeutics, Inc. (Nasdaq: SBTX) reported its third quarter financial results for the period ending September 30, 2021. The company incurred a net loss of $22.7 million, up from $8.1 million in the same period last year. R&D expenses surged to $15.6 million compared to $6.2 million in Q3 2020, reflecting increased clinical development efforts. Silverback also highlighted progress in its pipeline, including SBT6050's Phase 1/1b study and the upcoming initiation of SBT6290 and SBT8230 trials, with cash reserves at $340.6 million to fund operations through 2024.
Silverback Therapeutics, Inc. (SBTX), a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright Hepatitis B Virus Conference on October 13, 2021. CEO Laura Shawver and President Valerie Odegard will conduct a fireside chat at 10:30 a.m. ET (7:30 a.m. PT). The presentation will also be available via live webcast on Silverback’s investor relations website. Silverback utilizes its ImmunoTAC technology to develop targeted therapeutics for cancer and chronic viral infections.
Silverback Therapeutics (SBTX) announced interim results from a Phase 1/1b study of SBT6050, demonstrating activation of myeloid and T/NK cells and significant payload localization within the tumor microenvironment. The treatment showed a manageable safety profile and early anti-tumor activity among heavily pre-treated patients with advanced HER2-expressing solid tumors, including a confirmed partial response in one case. The company plans to expand clinical development and discuss the strategy in an upcoming conference call.
Silverback Therapeutics (NASDAQ: SBTX) announced interim data from the Phase 1/1b trial of SBT6050, aimed at advanced HER2-expressing solid tumors, will be presented at the ESMO 2021 Congress from September 16-21, 2021. The poster will reveal data from April 4, 2021, and additional insights from August 1, 2021. A conference call with management is scheduled for September 16, 2021, at 6:30 AM ET. SBT6050 utilizes ImmunoTAC technology to activate myeloid cells in tumors, targeting HER2 specifically. This could enhance treatment effectiveness in immuno-oncology.